**Supplementary Figure 1 –** *DCDs inhibit Met-mediated anchorage-dependent growth of Met-addicted cells.* Growth of Met-addicted gastric carcinoma cells treated with increasing concentrations of MvDN30, DCD-1 or DCD-2 for 3 days. **A.** MKN-45 cells; **B.** SNU-5 cells. Graphs represent percentage of average growth for each treatment with respect to untreated cells. Samples are in quadruplicates, bars: SEM. Data reported in the figure are representative of two experiments done.

Supplementary Figure 2 – *DCDs do not display inhibitory properties against cells in which Met is not active.* **A.** Anchorage-dependent growth of A549 lung carcinoma cells treated with increasing concentrations of MvDN30, DCD-1 or DCD-2 for 3 days. Graph represents percentage of average growth for each treatment with respect to untreated cells. Samples are in quadruplicates, bars: SEM. **B.** Anchorage-independent growth of A549 cells treated with the different DN30-derived molecules (1.5 μM). Graph represents the percentage of the average colony growth for each treatment with respect to untreated cells. Samples are in triplicates, bars: SEM. Data reported in the figure are representative of two experiments done.

Supplementary Figure 3 – *DCDs inhibit growth of Met-amplified cells derived from a colorectal carcinoma 'xenopatient'.* Growth of M162 patient-derived Met-amplified cells treated with MvDN30, DCD-1 or DCD-2 (all the molecules: 2 μM) for 3 days. Graph represents percentage of average growth for each treatment with respect to untreated cells. Each point is the mean of triplicate values, bars: SEM. ***, Student's t Test *p*<0.001. Data reported in the figure are representative of two experiments done.